Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: Further evidence for a link between microalbuminuria and endothelial dysfunction—The Hoorn Study  by Stehouwer, Coen D.A. et al.
Kidney International, Vol. 66, Supplement 92 (2004), pp. S42–S44
Microalbuminuria is associated with impaired brachial artery,
flow-mediated vasodilation in elderly individuals without
and with diabetes: Further evidence for a link between
microalbuminuria and endothelial dysfunction—The
Hoorn Study
COEN D.A. STEHOUWER, RONALD M.A. HENRY, JACQUELINE M. DEKKER, GIEL NIJPELS,
ROBERT J. HEINE, and LEX M. BOUTER
Departments of Internal Medicine and Endocrinology, Institutes for Cardiovascular Research and for Research in Extramural
Medicine, VU University Medical Center, Amsterdam, The Netherlands
Microalbuminuria is associated with impaired brachial artery,
flow-mediated vasodilation in elderly individuals without and
with diabetes: Further evidence for a link between microalbu-
minuria and endothelial dysfunction—The Hoorn Study.
Background. Extensive endothelial dysfunction (i.e., affect-
ing many aspects of endothelial function) has been hypothe-
sized to explain why microalbuminuria (MA) is associated with
cardiovascular disease risk. However, it is not clear whether MA
is specifically associated with impaired endothelial nitric oxide
(NO) synthesis in individuals without and with type 2 diabetes.
Methods. We did a population-based study in 645 individu-
als (mean age 68 years; 248 with normal glucose metabolism,
137 with impaired glucose metabolism, and 260 with type 2 di-
abetes) and investigated associations of MA [present (urinary
albumin-creatinine ratio ≥2 mg/mmol) versus absent, and in
four categories (<2, ≥2 to 5, ≥5 to 10, ≥10 mg/mmol)] with ul-
trasonically measured brachial artery endothelium-dependent,
flow-mediated (FMD; an estimate of endothelial NO synthesis)
and endothelium-independent, nitroglycerin-induced vasodila-
tion (NID).
Results. FMD was 0.12 mm in the presence of MA (N = 93;
49 with diabetes), and 0.18 in its absence (P = 0.002). After
adjustment for age, sex, baseline arterial diameter, and other
potential confounders, FMD was 0.038 mm (95% CI, 0.001 to
0.075) lower in the presence of MA (P = 0.04), and decreased
linearly across MA categories [by 0.027 mm (0.007 to 0.046) per
category increase of MA; P = 0.007]. NID was similar in individ-
uals with and without MA. Results were similar in individuals
without and with diabetes.
Conclusion. Microalbuminuria is linearly associated with im-
paired endothelium-dependent, flow-mediated vasodilation in
elderly individuals without and with diabetes. These findings
support the concept that impaired endothelial nitric oxide syn-
thesis plays a role in the association of microalbuminuria with
cardiovascular disease risk.
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In diabetes, much of the disease burden occurs in pa-
tients with diabetic nephropathy because they have the
highest chance of developing not only renal failure, but
also cardiovascular disease, severe retinopathy, and se-
vere neuropathy. The association between renal and car-
diovascular disease is seen even in individuals with early
nephropathy [microalbuminuria (MA)], and exists re-
gardless of the presence of diabetes. One hypothesis to
explain the link between MA and cardiovascular disease
is that extensive endothelial dysfunction (ED) represents
the common antecedent to both.
ED can be defined as any change in endothe-
lial properties that is inappropriate with regard to
the preservation of organ function. Therefore, many
types of ED exist, depending on which function is af-
fected (e.g., the regulation of hemostasis and fibrinoly-
sis, vasomotor activity, permeability to macromolecules,
leukocyte adhesion, or vascular smooth muscle cell
proliferation). Nitric oxide (NO) is a particularly im-
portant endothelium-derived mediator because of its va-
sodilator, anti-platelet, anti-proliferative, anti-adhesive,
permeability-decreasing, and anti-inflammatory proper-
ties. Generalized ED (i.e., affecting many functions) is
now considered a transducer of atherogenic risk factors,
and is thought to play an important role both in the initia-
tion and the progression of atherosclerosis. Therefore, an
association of MA with generalized ED, if it exists, could
explain the fact that MA strongly predicts cardiovascular
disease.
MA in type 1 and 2 diabetes is usually [1, 2], but per-
haps not always [2], accompanied by ED with regard to
the regulation of hemostasis, fibrinolysis, leukocyte ad-
hesion, and NO synthesis and/or availability (i.e., ED is,
at the very least, extensive). Whether this occurs in all
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vascular beds is extremely difficult to test in humans, but
is obviously an important question. There are fewer data
on the extent of ED in nondiabetic individuals with MA,
but such ED has, as in diabetes, been suggested to involve
the regulation of hemostasis, fibrinolysis, and leukocyte
adhesion [2–5]. However, it is controversial whether NO
synthesis and/or availability are impaired in nondiabetic
individuals with MA [5–7].
To investigate this issue more fully, we examined
brachial artery, flow-mediated vasodilation (FMD; an es-
timate of endothelium-derived NO synthesis) in elderly
individuals without and with MA in the population-based
Hoorn Study.
METHODS
The population has been described in detail elsewhere
[8, 9]. MA was defined as urinary albumin-creatinine ra-
tio (ACR) ≥2 mg/mmol (based on a single first-voided
morning urine sample). FMD and nitroglycerin-induced,
endothelium-independent dilation (NID) were measured
by ultrasound as described elsewhere [9, 10]. We used
multivariate linear regression to analyze associations of
MA [present vs. absent and in four categories (<2, ≥2 to
5, ≥5 to 10, ≥10 mg/mmol)] with FMD and NID.
RESULTS
Table 1 shows the characteristics of the study popula-
tion. Ninety-three individuals had MA (49 with diabetes;
53, 20, and 20 with ACR ≥2 to 5, ≥5 to 10, and ≥10 mg/
mmol, respectively). FMD was 0.12 mm in the presence
of MA and 0.18 in its absence (P = 0.002; Table 2).
After adjustment for age, sex, baseline arterial diame-
ter, and increase in peak systolic velocity, FMD was 0.038
mm (95% CI, 0.001 to 0.075) lower in the presence of MA
(P = 0.04) and decreased linearly across MA categories
[by 0.027 mm (0.007 to 0.046) per category increase of
MA; P = 0.007; Table 3, model 3]. Additional adjustments
did not materially affect these results (Table 3, models
4–11). NID was similar in individuals with and without
MA. All results were similar in individuals without and
with diabetes [P for interaction of diabetes with MA in
model 5 of Table 3 = 0.9 (dichotomized) and = 0.62 (in
categories), respectively], and whether or not individuals
with ACR >30 mg/mmol (N = 4) were excluded.
DISCUSSION
The major new finding of this population-based study
is that FMD is impaired in elderly individuals with MA
whether or not they have type 2 diabetes. Together with
previous data [3–6], this supports the concept that ED is
extensive even in nondiabetic individuals with MA and
that such extensive ED, including impaired endothelial
nitric oxide synthesis and/or availability, plays a role in
Table 1. Characteristics of the study population according to the
presence or absence of microalbuminuria
Micro- Micro-
albuminuria albuminuria
present absent P value
Number
(men/women)
93 (55/38) 552 (265/287) –
Age years 70 ± 8 67 ± 4 .006
Blood pressure
mm Hg
151 ± 18/81 ± 10 141 ± 19/76 ± 9 <.001/<.001
Hypertension % 82 66 <.001
Antihypertensive
medication %
48 33 <.001
Total cholesterol
mmol/L
5.5 ± 1.1 5.8 ± 1.0 .02
HDL cholesterol
mmol/L
1.3 ± 0.4 1.4 ± 0.4 0.50
LDL cholesterol
mmol/L
3.4 ± 0.9 3.7 ± 0.9 0.25
Triglycerides
mmol/L
1.4 (1.1–1.9) 1.4 (1.0–1.9) .51
Lipid-lowering
medication %
22 15 <.001
Body mass index
kg/m2
28 ± 4 27 ± 4 .49
Waist-to-hip ratio 0.95 ± 0.09 0.92 ± 0.10 .01
Smoking % 22 14 .048
Prior cardiovascular
disease %
64 44 <.001
Serum creatinine
lmol/L
100 ± 25 93 ± 14 <.001
NGM/IGM/DM-2 N 22/22/49 226/115/211 –
Abbreviations are: NGM, normal glucose metabolism; IGM, impaired glucose
metabolism; DM-2, type 2 diabetes. Results are mean ± standard deviation or
median (interquartile range).
Table 2. Brachial arterial properties according to the presence or
absence of microalbuminuria
Micro- Micro-
albuminuria albuminuria
present Absent P value
Diameter mm
Baseline diameter 4.87 ± 0.80 4.64 ± 0.74 .006
After endothelium-dependent
dilation
4.98 ± 0.80 4.81 ± 0.73 .04
After endothelium-independent
dilation
5.28 ± 0.80 5.08 ± 0.73 .02
Absolute change in diameter mm
After endothelium-dependent
dilation
0.12 ± 0.13 0.18 ± 0.17 .002
After endothelium-independent
dilation
0.42 ± 0.23 0.45 ± 0.23 .12
Peak systolic velocity cm/s
At baseline 61 ± 12 58 ± 13 .02
After endothelium-dependent
dilation
106 ± 26 106 ± 26 .96
Percentage increase from baseline 76 ± 42 87 ± 43 .02
the association of MA with cardiovascular disease risk in
nondiabetic individuals.
It must be emphasized that prospective studies are
needed to test whether ED actually explains the link be-
tween MA and cardiovascular disease. Of three previous
studies that used plasma markers of ED [4, 11, 12], two
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Table 3. Flow-mediated, endothelium-dependent vasodilation (absolute change in diameter) and microalbuminuria: Adjusted analyses
Microalbuminuria Microalbuminuria P trend for categories
Model yes vs. no b (95% CI) P value categories b (95% CI)a of microalbuminuriaa
1. (Micro-)albuminuria −0.058 (−0.096 to −0.022) <.001 −0.035 (−0.055 to −0.015) .001
2. 1 + baseline diameter + % increase −0.044 (−0.082 to −0.007) .02 −0.028 (−0.048 to −0.008) .007
in peak systolic velocity
3. 2 + sex + age −0.038 (−0.075 to −0.001) .04 −0.027 (−0.046 to −0.007) .007
4. 3 + hypertensionb −0.034 (−0.071 to 0.003) .07 −0.025 (−0.045 to −0.006) .01
5. 3 + glucose tolerance status −0.038 (−0.067 to 0.006) .10 −0.022 (−0.041 to −0.002) .03
6. 3 + body mass index −0.037 (−0.074 to −0.001) .05 −0.026 (−0.046 to −0.007) .008
7. 3 + waist-to- hip ratio −0.035 (−0.072 to 0.002) .06 −0.025 (−0.045 to −0.005) .01
8. 3 + smoking −0.031 (−0.068 to 0.005) .09 −0.023 (−0.042 to −0.003) .02
9. 3 + prior cardiovascular disease −0.028 (−0.066 to 0.009) .14 −0.020 (−0.042 to −0.002) .03
10. 3 + serum creatinine −0.041 (−0.078 to −0.005) .03 −0.031 (−0.050 to −0.011) .003
11. 3 + total cholesterolc −0.037 (−0.074 to −0.001) .04 −0.027 (−0.046 to −0.007) .008
aSee Methods.
bResults were similar if hypertension was replaced by systolic, diastolic, pulse, or mean pressure, or the use of antihypertensive medication.
cResults were similar if total cholesterol was replaced by HDL cholesterol, LDL cholesterol, triglycerides, or the use of lipid-lowering medication.
[4, 11] found no strong evidence in favor of this hypoth-
esis, which may mean that ED was not measured with
sufficient precision, that the types of ED tested were ir-
relevant with regard to cardiovascular risk in MA, or that
ED, although associated with MA, does not explain the
MA-cardiovascular disease link.
Because ED precedes and predicts the onset of MA
[3, 4, 11–13], it is tempting to postulate that ED causes
MA. Alternatively, the association between ED and MA
could be explained by a common antecedent that causes
both, but the association persists when adjusted for com-
mon risk factors. Theoretically, ED could cause MA both
directly by increasing glomerular pressure and glomeru-
lar basement membrane permeability, and indirectly by
influencing mesangial cell and podocyte function in a
paracrine fashion (e.g., through inflammatory mecha-
nisms). Importantly, the molecular pathways by which
ED causes MA have yet to be worked out [2].
CONCLUSION
ED in individuals with MA is usually extensive (i.e.,
affects many aspects of endothelial function) regardless
of the presence of diabetes. The close linkage between
MA and ED is an attractive but unproven explanation for
the fact that MA is a risk marker for atherothrombosis.
ED predicts the occurrence of MA, but whether this is
causal has not been determined.
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